Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Novel Therapeutic Targets and Drug Development in Retinal Diseases"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 10 June 2023 | Viewed by 4265
Special Issue Editor
Interests: photoreceptors; retinal degeneration; proteostasis; neuroprotection; drug delivery; animal models; organotypic cultures
Special Issue Information
Many ocular diseases caused by endogenous or exogenous insults lead to photoreceptor cell death, the ultimate cause of vision loss in various retinal diseases, which are currently not properly treated despite the increasing prevalence. The light-sensitive photoreceptor cells are terminally differentiated neurons that are not regenerated after degeneration or injury in adult mammals. The high heterogeneity of factors inducing photoreceptor degeneration hampers the development of effective therapeutic interventions. Several cellular and biochemical processes can contribute to photoreceptor death, including endoplasmic reticulum stress and unfolded protein response, oxidative stress, and inflammation, offering a vast repertoire of potential therapeutic targets.
This Special Issue entitled “Novel Therapeutic Targets and Drug Development in Retinal Diseases” will contribute to understanding disease mechanisms better, opening novel avenues for targeting photoreceptor degeneration and accelerating the development and characterization of compounds for preclinical studies as a starting point for advanced drug development.
Dr. Blanca Arango-Gonzalez
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- therapeutic target
- retinitis pigmentosa
- retinal degeneration
- photoreceptor cell death
- oxidative stress
- ER stress